Lupus & Connective Tissue Diseases
From the Journals
U.S. arthritis prevalence continues steady rise; activity limitations grow more rapidly
The latest survey data indicated that more Americans have arthritis than ever before, possibly because of an aging population, worsening...
News from the FDA/CDC
Adalimumab biosimilar Cyltezo gets interchangeability designation
The approval of the supplemental biologics license application for Cyltezo makes the adalimumab biosimilar just the second biosimilar to be...
Conference Coverage
Lupus may confer higher risk of death from COVID-19
SLE had a greater impact on mortality and other poor outcomes than did all the other comorbidities considered in a cross-sectional study of COVID-...
Conference Coverage
Low preconception complement levels linked to adverse pregnancy outcomes in antiphospholipid syndrome
Low levels of C3 and C4 in the 6 months prior to pregnancy were associated with several gestational and maternal complications and resulted in...
News from the FDA/CDC
FDA approves avacopan for rare ANCA autoimmune disease
ChemoCentryx said it plans to price its new medicine at an annual cost of $150,000-$200,000 for U.S. patients.
Feature
NIAMS director reflects on her mentors, spotlights research projects underway
“Ultimately, I want to contribute to the great work of the Institute and improve the lives of people with rheumatic, musculoskeletal, and skin...
Feature
Acceptance of biosimilars grows but greater use may hinge on switching, interchangeability studies
The slow adoption of biosimilars in the United States has begun to pick up and experts hope that they can put a brake on drug spending, but...
From the Journals
Temporary hold of mycophenolate helps immune response to SARS-CoV-2 vaccination
A comparison of patients with rheumatic and musculoskeletal diseases shows that withholding mycophenolate around the time of vaccination can be...
Conference Coverage
Fibrosis progression flies below the radar in subclinical ILD
Patients with connective tissue diseases should be monitored for subclinical interstitial lung disease and fibrosis, experts say.
Conference Coverage
Emerging data point to underlying autoimmunity in ME/CFS
Findings suggest that potential treatments targeting autoantibodies may alleviate symptoms.
Feature
NIH to study COVID vaccine booster in people with autoimmune disease
The trial will look at the impact of a booster in patients with five different autoimmune diseases who are either on or off immunosuppressives.